Highlight
The addition of tiragolumab, an anti-TIGIT monoclonal antibody, to atezolizumab and chemotherapy resulted in a confirmed objective response rate (ORR) of 67.7%, compared to 53.8% for atezolizumab plus chemotherapy and 47.8% for chemotherapy alone.
The triple-drug combination maintained a manageable safety profile, with grade 3-4 adverse events occurring at rates similar to the doublet and chemotherapy-only arms (79% vs 80% and 74%, respectively).
